Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Bags Exclusive Rights To Develop, Sell Debiopharm’s Xevinapant

The IAP antagonist Is In Phase III Trials For Head And Neck Cancer

Executive Summary

Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.

You may also be interested in...



Merck KGaA Keeps Powder Dry On Licensing Deals

After doing a number of healthcare deals in 2021, it looks as though Merck KGaA will keep M&A activity to a minimum for the division this year, focusing instead on advancing its own promising candidates for cancer, multiple sclerosis and lupus.

Merck KGaA In The Market For Bolt-On M&A

Belén Garijo, the German group's CEO, has told analysts she considers targeted smaller to medium-sized acquisitions to be more likely than major transformational deals but said that "we are always open to something bolder."

Biliary Tract Cancer Fail Is Another Blow for Merck KGaA/GSK's Bintrafusp

Less than two months after bintrafusp failed to beat Merck & Co's blockbuster Keytruda in a Phase III NSCLC trial, Merck KGaA's bispecific fusion protein partnered with GSK has disappointed in a mid-stage study for biliary tract cancer.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC143906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel